Abstract 5334
Background
Women with OC due to an underlying BRCAm have enhanced responses to platinum and often improved progression free survival. BRCAm carriers also have an increased risk of BC, which often predates OC and may impact later treatment response.
Methods
Women with OC treated at The Royal Marsden Hospital between 01/06/13 and 31/5/17 with known BRCAm status were identified from the electronic patient record. The primary endpoint was progression free survival (PFS) after first line treatment for OC, stratified for BRCAm and BC status. Secondary endpoints were time to second subsequent treatment (TSST) and type of BRCA mutation (BRCA1 vs BRCA2).
Results
575 patients were identified, 502 high grade (HG), 73 low grade (LG) OC. Histology was HG serous (77%), endometroid (10%), clear cell (5%), LG serous (4%), other (4%). 158 (27%) had a BRCAm, 92 (58%) BRCA1 and 66 (42%) BRCA2. Mean age of OC diagnosis was 59 (19-98) yrs. Prior BC was noted in 79 patients – 51 BRCAm, 28 WT; 21 patients had >1 BC (14 BRCA, 7 WT). Mean age of first BC diagnosis was 50 yrs (30-75). Median PFS (mths) was 19.6 (BC, WT) vs 23.6 (no BC, WT) vs 25.4 (BC, BRCAm) vs 27.1 (no BC, BRCAm), p = 0.08. TSST(mths) was significantly different at 23.1 (BC, WT) vs 30 (no BC, WT) vs 34 (BC, BRCAm) vs 42.6 (no BC, BRCAm), p = 0.02. There was no significant difference in PFS between those who did/did not receive chemotherapy for prior breast cancer; nor between those with a BRCA1 vs BRCA2 mutation.
Conclusions
Within the limits of a retrospective audit, there was no significant difference in PFS for women with OC irrespective of prior BC diagnosis or BRCAm status, but there was a significant difference in TSST. A similar trend was seen in both groups, with poorest PFS/TSST in those with prior BC/BRCA WT; and best PFS/TSST in those with no prior BC/BRCAm. Prior BC diagnosis may be another factor in response to OC chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2674 - Multicenter Phase I Trial of Trastuzumab Emtansine (T-DM1) in Combination with Non-Pegylated Liposomal Doxorubicin (NPLD) in HER2[+] Metastatic Breast Cancer (MBC). THELMA Study
Presenter: Elena López-Miranda
Session: Poster Display session 2
Resources:
Abstract
1398 - Phase 1 study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumors: primary results of dose-escalation part
Presenter: Noboru Yamamoto
Session: Poster Display session 2
Resources:
Abstract
5818 - Polo-like Kinase 1 inhibitor onvansertib synergizes with paclitaxel in breast cancer carrying p53 mutation
Presenter: Antonio Giordano
Session: Poster Display session 2
Resources:
Abstract
5927 - Phase 1b study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173).
Presenter: Robert Wesolowski
Session: Poster Display session 2
Resources:
Abstract
1695 - Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: results from the AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: Poster Display session 2
Resources:
Abstract
1742 - Clinical profile and outcome of HER2 positive breast cancer patients with brain metastases treated with HER2 targeted therapy: Real world experience.
Presenter: Prabhat Bhargava
Session: Poster Display session 2
Resources:
Abstract
1846 - Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: results of single arm phase IV COMACHI study
Presenter: Norikazu Masuda
Session: Poster Display session 2
Resources:
Abstract
5385 - Anti HER-2 Therapies and Left Ventricular Dysfunction The Renaissance Study
Presenter: ANDRES DANIELE
Session: Poster Display session 2
Resources:
Abstract
3320 - Safety and efficacy of T-DM1 in 128 patients with advanced HER2+ breast cancer: The Royal Marsden experience.
Presenter: Nicolò Battisti
Session: Poster Display session 2
Resources:
Abstract
4540 - Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): challenges in assessing effectiveness of treatment sequencing in the real world (RW)
Presenter: Thibaut Sanglier
Session: Poster Display session 2
Resources:
Abstract